Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Esperion Therapeutics Initiates Phase 2 Clinical Study for ETC-1002

January 6, 2011 By Bio-Medicine.Org

PLYMOUTH, Mich., Jan. 6, 2011 /PRNewswire/ — Esperion
Therapeutics, a privately held biotechnology company working to
discover, develop and commercialize treatments for cardiovascular
and metabolic diseases, today announced that it has initiated a
Phase 2 clinical study for ETC-1002, the company’s lead product
candidate. ETC-1002 is a novel small molecule compound that has
demonstrated preclinical and clinical activity as a metabolic
regulator of imbalances in lipid and carbohydrate metabolism. The
compound acts to inhibit fatty acid and cholesterol synthesis and
enhance fatty acid oxidation. ETC-1002 has the potential to
regulate LDL-C, HDL-C, triglycerides, glucose/insulin and other
cardio-metabolic risk factors.

The 12-week, multi-site, randomized, double-blind, placebo
controlled study will enroll 176 patients with
hypercholesterolemia, with or without high triglycerides, to assess
the role of ETC-1002 in lipid regulation (LDL-C and triglycerides).
This Phase 2 trial builds on positive data from the Phase 1 program
in which ETC-1002 demonstrated a statistically significant lowering
of LDL-C in mildly dyslipidemic subjects and a favorable safety
profile in both single and multiple-dose studies in more than 70
patients. A second Phase 2 clinical study is planned in 2011 to
validate other attributes observed in preclinical studies with
ETC-1002 which further support its pharmacological effects as a
metabolic regulator.

“Cardio-metabolic diseases remain the leading cause of morbidity
and mortality among men and women in industrialized countries
worldwide,” said Roger Newton, PhD, President and CEO of Esperion.
“Our preclinical research has shown ETC-1002 regulates lipids,
atherosclerosis, inflammation and glucose/insulin. These data,
along with the accumulating clinical evidence, suggest that
ETC-1002 may be an effective therapy to regulate metabolic
imbalances in lipid and carbohydrate metabolism and could play a
significant role in the treatment

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 27, 2022
Quick message - No DTW podcast, but plenty else to listen to over this weekend and next week.
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech